Piramal Pharma Receives FDA Form 483 With VAI Observations at U.S. Plant

Piramal Pharma Limited ( (IN:PPLPHARMA) ) has issued an announcement.

Piramal Pharma Limited reported that the U.S. FDA conducted a Good Manufacturing Practices inspection at its Sellersville, U.S., facility from May 4 to May 8, 2026, resulting in a Form 483 with three observations classified as Voluntary Action Indicated. None of the findings involved data integrity, and the company plans to submit a detailed response within required timelines while working closely with the regulator to resolve all issues.

The announcement signals that the observations are not considered severe by the inspectors, suggesting limited immediate regulatory risk for the facility’s operations. However, the outcome underscores ongoing regulatory scrutiny in the pharmaceutical sector and highlights Piramal Pharma’s need to maintain robust compliance to protect its U.S. business and reassure investors and customers about product quality and reliability.

More about Piramal Pharma Limited

Piramal Pharma Limited is an India-based pharmaceutical company operating globally with a focus on manufacturing and supplying pharmaceutical products and services. The company runs facilities in markets such as the U.S., supporting its position as a producer for regulated markets under stringent quality and compliance standards.

Average Trading Volume: 240,166

Technical Sentiment Signal: Buy

Current Market Cap: 238.9B INR

See more data about PPLPHARMA stock on TipRanks’ Stock Analysis page.